XOMA Corporation (NASDAQ:XOMA) vs. The Competition Financial Survey

XOMA Corporation (NASDAQ: XOMA) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare XOMA Corporation to related companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, earnings and dividends.

Earnings & Valuation

This table compares XOMA Corporation and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
XOMA Corporation $12.31 million -$30.55 million -3.22
XOMA Corporation Competitors $224.52 million $58.08 million -1.10

XOMA Corporation’s competitors have higher revenue and earnings than XOMA Corporation. XOMA Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

32.9% of XOMA Corporation shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 3.0% of XOMA Corporation shares are held by insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

XOMA Corporation has a beta of 3.2, indicating that its share price is 220% more volatile than the S&P 500. Comparatively, XOMA Corporation’s competitors have a beta of 1.13, indicating that their average share price is 13% more volatile than the S&P 500.

Profitability

This table compares XOMA Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XOMA Corporation -329.42% N/A -155.46%
XOMA Corporation Competitors -910.58% -183.99% -27.07%

Analyst Recommendations

This is a summary of current ratings and target prices for XOMA Corporation and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Corporation 0 2 2 0 2.50
XOMA Corporation Competitors 123 463 1161 11 2.60

XOMA Corporation currently has a consensus price target of $28.50, indicating a potential upside of 20.87%. As a group, “Biotechnology” companies have a potential upside of 67.34%. Given XOMA Corporation’s competitors stronger consensus rating and higher probable upside, analysts clearly believe XOMA Corporation has less favorable growth aspects than its competitors.

Summary

XOMA Corporation competitors beat XOMA Corporation on 8 of the 12 factors compared.

About XOMA Corporation

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.